Browsing Tag
Bell Potter Securities Limited
3 posts
Paradigm Biopharmaceuticals (ASX: PAR) raises A$14m as Phase 3 osteoarthritis trial enters decisive window
Paradigm Biopharmaceuticals has more cash, but Zilosul still needs Phase 3 proof. ASX:PAR now turns from funding risk to data risk.
IperionX capitalizes on titanium demand with A$100m placement
IperionX Limited (NASDAQ: IPX, ASX: IPX) has secured A$100 million through a placement of 31,250,000 new fully paid…
Spacetalk Limited unveils AUD3.2m equity raising to fuel product development and growth
Spacetalk Limited has announced a partially underwritten $3.2 million AUD equity raising to bolster its inventory purchase, data-led…